Terms: = Kidney tumors AND MTOR, FRAP2, FRAP1, 2475, ENSG00000198793, P42345, RAPT1, RAFT1, FRAP, FLJ44809 AND Treatment
818 results:
1.
Miao X; Jiang P; Zhang X; Li X; Wu Z; Jiang Y; Liu H; Xie W; Li X; Shi B; Cai J; Gong W
Microbiol Spectr; 2024 May; 12(5):e0183923. PubMed ID: 38564670
[TBL] [Abstract] [Full Text] [Related]
2. Lymphangioleiomyomatosis in patients with tuberous sclerosis: a national centre audit.
Johnson J; Somerfield W; Johnson SR
Orphanet J Rare Dis; 2024 Mar; 19(1):137. PubMed ID: 38532450
[TBL] [Abstract] [Full Text] [Related]
3. Hereditary Renal Cancer Syndromes.
Yanus GA; Kuligina ES; Imyanitov EN
Med Sci (Basel); 2024 Feb; 12(1):. PubMed ID: 38390862
[TBL] [Abstract] [Full Text] [Related]
4. Tumorigenic role of tacrolimus through mtorC1/C2 activation in post-transplant renal cell carcinomas.
Moldvai D; Sztankovics D; Dankó T; Vetlényi E; Petővári G; Márk Á; Patonai A; Végső G; Piros L; Hosszú Á; Pápay J; Krencz I; Sebestyén A
Br J Cancer; 2024 Apr; 130(7):1119-1130. PubMed ID: 38341510
[TBL] [Abstract] [Full Text] [Related]
5. Pterostilbene and 6-shogaol exhibit inhibitory effects on sunitinib resistance and motility by suppressing the RLIP76-initiated Ras/ERK and Akt/mtor pathways in renal cancer cells.
Chiang IC; Chen SY; Hsu YH; Shahidi F; Yen GC
Eur J Pharmacol; 2024 Mar; 967():176393. PubMed ID: 38325792
[TBL] [Abstract] [Full Text] [Related]
6. Cemiplimab for kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma.
Hanna GJ; Dharanesswaran H; Giobbie-Hurder A; Harran JJ; Liao Z; Pai L; Tchekmedyian V; Ruiz ES; Waldman AH; Schmults CD; Riella LV; Lizotte P; Paweletz CP; Chandraker AK; Murakami N; Silk AW
J Clin Oncol; 2024 Mar; 42(9):1021-1030. PubMed ID: 38252908
[TBL] [Abstract] [Full Text] [Related]
7. Cerebral vascular and blood brain-barrier abnormalities in a mouse model of epilepsy and tuberous sclerosis complex.
Guo D; Zhang B; Han L; Rensing NR; Wong M
Epilepsia; 2024 Feb; 65(2):483-496. PubMed ID: 38049961
[TBL] [Abstract] [Full Text] [Related]
8. Hybrid Management of a Wünderlich's Syndrome Secondary to a Giant Ruptured Renal Angiomyolipoma: A Case Report.
Bellouki O; Bakouch M; Ibrahimi A; Boualaoui I; El Aoufir O; Zouaidia F; Benhadda S; El Sayegh H; Nouini Y
Urology; 2024 Feb; 184():e246-e249. PubMed ID: 38043904
[TBL] [Abstract] [Full Text] [Related]
9. Effectiveness and safety of everolimus treatment in patients with tuberous sclerosis complex in real-world clinical practice.
Cockerell I; Christensen J; Hoei-Hansen CE; Holst L; Grenaa Frederiksen M; Issa-Epe AI; Nedregaard B; Solhoff R; Heimdal K; Johannessen Landmark C; Lund C; Nærland T
Orphanet J Rare Dis; 2023 Dec; 18(1):377. PubMed ID: 38042867
[TBL] [Abstract] [Full Text] [Related]
10. Glutamine synthetase and hepatocellular carcinoma.
Jiang J; Hu Y; Fang D; Luo J
Clin Res Hepatol Gastroenterol; 2023 Dec; 47(10):102248. PubMed ID: 37979911
[TBL] [Abstract] [Full Text] [Related]
11. Impact of Immunotherapy on Real-World Survival Outcomes in Metastatic Renal Cell Carcinoma.
Poprach A; Kiss I; Stanik M; Barusova T; Pospisilova L; Fiala O; Kopecky J; Richter I; Melichar B; Studentova H; Lakomy R; Holanek M; Rozsypalova A; Zemanková A; Svoboda M; Buchler T
Target Oncol; 2023 Nov; 18(6):893-903. PubMed ID: 37957520
[TBL] [Abstract] [Full Text] [Related]
12. Molecular insight into renal cancer and latest therapeutic approaches to tackle it: an updated review.
Murali R; Gopalakrishnan AV
Med Oncol; 2023 Nov; 40(12):355. PubMed ID: 37955787
[TBL] [Abstract] [Full Text] [Related]
13. Baicalein improves the chemoresistance of ovarian cancer through regulation of CirSLC7A6.
Li S; Yi Z; Li M; Zhu Z
J Ovarian Res; 2023 Nov; 16(1):212. PubMed ID: 37940982
[TBL] [Abstract] [Full Text] [Related]
14. Combining MTI-31 with RAD001 inhibits tumor growth and invasion of kidney cancer by activating autophagy.
Zhang W; Yang C; Zou L; Zang Y; Hu J; Hu Y; Xu C; Liu R; Wang H; Xiong Z
J Appl Genet; 2024 Feb; 65(1):103-112. PubMed ID: 37932653
[TBL] [Abstract] [Full Text] [Related]
15. Renal Cell Cancer - Insights in Drug Resistance Mechanisms.
Aweys H; Lewis D; Sheriff M; Rabbani RD; Lapitan P; Sanchez E; Papadopoulos V; Ghose A; Boussios S
Anticancer Res; 2023 Nov; 43(11):4781-4792. PubMed ID: 37909991
[TBL] [Abstract] [Full Text] [Related]
16. Comprehensive exploration of Biochanin A as an oncotherapeutics potential in the treatment of multivarious cancers with molecular insights.
Sohel M
Phytother Res; 2024 Feb; 38(2):489-506. PubMed ID: 37905329
[TBL] [Abstract] [Full Text] [Related]
17. Genomic Profiling and Molecular Characterization of Clear Cell Renal Cell Carcinoma.
Pezzicoli G; Ciciriello F; Musci V; Salonne F; Ragno A; Rizzo M
Curr Oncol; 2023 Oct; 30(10):9276-9290. PubMed ID: 37887570
[TBL] [Abstract] [Full Text] [Related]
18. Identification of a Novel TSC2 c.170G>A Missense Variant: A Case Report and Elaboration on the Yield of Targeted Options against Tuberous Sclerosis Complex Manifestations.
Papageorgiou G; Skouteris N; Valavanis C; Stanc GM; Souka E; Charalampakis N
Rev Recent Clin Trials; 2023; 18(4):304-312. PubMed ID: 37877150
[TBL] [Abstract] [Full Text] [Related]
19. A Rare Presentation of Aggressive Renal Cell Carcinoma and the Utility of Early Molecular Testing in Rapidly Progressing Malignancies: A Case Report.
McLoughlin DE; Chevalier N; Choy E; Cote GM; Gao X; Juric D; Reynolds KL
Oncologist; 2023 Dec; 28(12):1094-1099. PubMed ID: 37844295
[TBL] [Abstract] [Full Text] [Related]
20. PLCL1 suppresses tumour progression by regulating AMPK/mtor-mediated autophagy in renal cell carcinoma.
Pan Z; Huang J; Song H; Xiao Y; Liu T; Zeng Y; Zhu H; Yang K
Aging (Albany NY); 2023 Oct; 15(19):10407-10427. PubMed ID: 37801481
[TBL] [Abstract] [Full Text] [Related]
[Next]
